|
WO2021071358A1
|
|
Immune cell quantification
|
|
IL275424D0
|
|
Means and methods for counteracting muscle disorders
|
|
WO2020130836A1
|
|
Compound for use in treatment and prevention of type i diabetes
|
|
CA3111971A1
|
|
Heating apparatus and methods
|
|
WO2020055240A1
|
|
Musk inhibition
|
|
WO2020055241A1
|
|
Musk activation
|
|
NL2023464B1
|
|
Oncolytic Non-human adenoviruses and uses thereof
|
|
WO2019231326A1
|
|
Teipp neoantigens and uses thereof
|
|
NL2022714B1
|
|
Optimised RAG1 deficient SCID Gene Therapy
|
|
CN112218949A
|
|
Inhibition of polyoma virus replication
|
|
NL2022291B1
|
|
Compound for Use in Treatment and Prevention of Type I Diabetes
|
|
US2020385341A1
|
|
Cathepsin inhibitors
|
|
NL2022013B1
|
|
Polypeptide Conjugates
|
|
US2020276441A1
|
|
System, method and catheter for pituitary and brain implantation
|
|
NL2021998B1
|
|
System and method for intermittent electrical modulation
|
|
EP3636635A1
|
|
Imaging agents
|
|
NL2021789A
|
|
Binding proteins specific for HA-1H and uses thereof
|
|
NL2021769B1
|
|
Fluid vessel insertion device with automatic needle retraction
|
|
NL2021722B1
|
|
Heating apparatus and methods
|
|
WO2019054865A1
|
|
T-cell based immunotherapy
|
